Rodrigo Alonso Moralejo

Dr. Rodrigo Alonso Moralejo

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2010 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
JCJavier Sayas Catalan
Javier Sayas Catalan
RLRicardo García Luján
Ricardo García Luján
MPMónica Coronado Poggio
Mónica Coronado Poggio
EMEduard Monsó Molas
Eduard Monsó Molas
ÁEÁngel López Encuentra
Ángel López Encuentra

22 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
MGMARIA PIEDAD USSETTI GIL
MARIA PIEDAD USSETTI GIL
APAlicia De Pablo
Alicia De Pablo
DFDavid Iturbe Fernández
David Iturbe Fernández
RLRosalía Laporta
Rosalía Laporta
JCJosé Manuel Cifrián
José Manuel Cifrián
Background: The clinical benefits of the common off-label use of cytomegalovirus (CMV)-specific immunoglobulin (CMV-Ig) combined with antivirals in organ transplantation have not been previously assessed. The objective was to compare the risk of CMV infection and other post-transplantation outcomes between two CMV-Ig prophylaxis regimens in lung transplant recipients; Methods: Retrospective study of 124 donor CMV positive/recipient negative (D+/R–) patients receiving preventive ganciclovir/valganciclovir for 12 months, of whom 62 received adjunctive CMV-Ig as per label indication (short regimen [SR-Ig]; i.e., 7 doses over 2.5 months) and were compared to 62 who received an extended off-label regimen (ER-Ig) consisting of 17 doses over one year after transplantation. Results: The incidence of CMV infection or disease, acute rejection, chronic lung allograft dysfunction, and survival did not differ between the two CMV-Ig schedules. Although the time to the first CMV infection after transplantation was shorter in the ER-Ig than in the SR-Ig adjunctive group (log-rank: p = 0.002), the risk was independently predicted by antiviral cessation (odds ratio = 3.74; 95% confidence interval = 1.04–13.51; p = 0.030), whereas the CMV-Ig schedule had no effect. Conclusions: Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer’s recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.

8 May 2024 in Life
Verified
Journal Article
Open access
PDF file
DIDavid Iturbe-Fernández
David Iturbe-Fernández
APAlicia De Pablo
Alicia De Pablo
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
CLCARLOS ANDRES QUEZADA LOAIZA
CARLOS ANDRES QUEZADA LOAIZA
JCJosé Manuel Cifrián
José Manuel Cifrián
Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment. Results: Fifty-seven patients were included in this study. The variation in the FEV1 was −102.7 (149.6) mL/month before starting everolimus compared to −44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and −7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5–25.1) months. Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients.

16 May 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
CSCiara M. Shaver
Ciara M. Shaver
CDCaitlin T. Demarest
Caitlin T. Demarest
DEDavid Erasmus
David Erasmus
Brian KellerBrian Keller
Brian Keller
KHKonrad Hötzenecker
Konrad Hötzenecker
Primary graft dysfunction (PGD) is a proinflammatory syndrome occurring within the first days following lung transplantation. It is initiated by ischemia-reperfusion injury and perpetuated by donor and recipient immunologic factors, resulting in alveolar damage and progressive hypoxemic respiratory failure.1 PGD is a known risk factor for both early allograft failure and chronic lung allograft dysfunction (CLAD).2 Incidence of severe PGD remains high at 10-25%, though is variable; risk factors for PGD include center experience, underlying recipient disease type, size matching, donor lung storage conditions, operative time, and post-operative management.2 Strategies to prevent PGD or mitigate the long -term consequences after it develops, are sorely needed. However, lack of specificity of the current PGD definition may hamper further progress in the field, especially as it pertains to the development of robust and relevant clinical trials. We propose that future modifications of the PGD definition incorporate more objective surrogates of allograft injury and subsequent diffuse alveolar damage, which may improve our ability to accurately study disease pathogenesis and improve outcomes.

21 October 2025
Verified
Journal Article
Open access
SOSusana Ramos Oliveira
Susana Ramos Oliveira
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
VPVirginia Pérez
Virginia Pérez
CQCarlos Andrés Quezada
Carlos Andrés Quezada
APAlicia de Pablo
Alicia de Pablo
FLFrancisco Lopez-Medrano
Francisco Lopez-Medrano
Revista Española de Quimioterapia tiene un carácter multidisciplinar y está dirigida a todos aquellos profesionales involucrados en la epidemiología, diagnóstico, clínica y tratamiento de las enfermedades infecciosas. Fundada en 1988 por la Sociedad Española de Quimioterapia.

2 March 2026 in Clinical Transplantation
Verified
Journal Article
Closed access
PTPedro Manso Tejerina
Pedro Manso Tejerina
QLQuezada Loaiza
Quezada Loaiza
CACarlos Andrés
Carlos Andrés
JIJuan Margallo Iribarnegaray
Juan Margallo Iribarnegaray
VGVirginia Luz Pérez González
Virginia Luz Pérez González
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo